US 12,440,573 B2
Antibody-conjugates for targeting of tumours expressing PTK7
Lianne Lelieveldt, Nijmegen (NL); Remon van Geel, Lithoijen (NL); Sander Sebastiaan van Berkel, Oss (NL); and Floris Louis van Delft, Nijmegen (NL)
Assigned to Synaffix B. V., Oss (NL)
Filed by Synaffix B.V., Oss (NL)
Filed on Sep. 20, 2024, as Appl. No. 18/892,253.
Application 18/892,253 is a continuation of application No. PCT/EP2023/057560, filed on Mar. 23, 2023.
Claims priority of application No. 22163924 (EP), filed on Mar. 23, 2022.
Prior Publication US 2025/0099601 A1, Mar. 27, 2025
Int. Cl. A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/40 (2006.01)
CPC A61K 47/68037 (2023.08) [A61K 47/6815 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07K 16/40 (2013.01)] 9 Claims
OG exemplary drawing
 
1. An antibody-conjugate according to general structure (1):
AB-[(L6)b-{Z-L-D}x]y  (1)
wherein:
AB is an anti-PTK7 antibody comprising a light chain and a heavy chain comprising the amino acid sequences set forth in SEQ ID NO: 20 and 19, respectively;
L6 is -GlcNAc(Fuc)w-(G)j-S-(L7)w′-;
G is selected from galactose, glucose, N-acetylgalactosamine, N-acetylglucosamine, mannose or N-acetylneuraminic acid;
j is an integer in the range of 0-10;
S is GalNAc;
GlcNAc is N-acetylglucosamine;
Fuc is fucose;
w is 0 or 1;
w′ is 0, 1 or 2;
b is 0 or 1;
x is 1 or 2;
y is 1, 2, 3 or 4;
L7 is —N(H)C(O)CH2—, —N(H)C(O)CF2— or —CH2—; and
—Z-L-D is:

OG Complex Work Unit Chemistry
wherein * is the point of attachment of —Z-L-D to L6,
or a pharmaceutically acceptable salt thereof.